Shiwanthi L Ranasinghe1, Mary Duke2, Marina Harvie2, Donald P McManus2. 1. Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: shiwanthi.ranasinghe@qimrberghofer.edu.au. 2. Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Abstract
OBJECTIVE: The aim of this study was to develop a vaccine against schistosomiasis, which is a major challenge due to the complex lifecycle of the causative schistosome parasite. METHODS: SmKI-1 is a 16-kDa Kunitz-type protease inhibitor present in the excretory-secretory products and tegument of adult worms and eggs of Schistosoma mansoni. Two independent vaccine trials were performed in mice to determine the efficacy of rSmKI-1 in developing protective immunity. RESULTS: The results obtained showed reductions of 23-33% in adult worms, 28-31% in intestinal eggs, 33-39% in faecal eggs, and 20-43% in liver eggs. Furthermore, rSmKI-1 significantly increased the production of interferon gamma, interleukin (IL)-10, and IL-6 in vaccinated mice, maintaining a Th1/Th2-type balanced protective response. CONCLUSIONS: rSmKI-1 generated partial protection against schistosomiasis mansoni in the murine model of infection and could be developed as part of a combination vaccine with other vaccine candidates to provide an even more solid level of protection.
OBJECTIVE: The aim of this study was to develop a vaccine against schistosomiasis, which is a major challenge due to the complex lifecycle of the causative schistosome parasite. METHODS: SmKI-1 is a 16-kDa Kunitz-type protease inhibitor present in the excretory-secretory products and tegument of adult worms and eggs of Schistosoma mansoni. Two independent vaccine trials were performed in mice to determine the efficacy of rSmKI-1 in developing protective immunity. RESULTS: The results obtained showed reductions of 23-33% in adult worms, 28-31% in intestinal eggs, 33-39% in faecal eggs, and 20-43% in liver eggs. Furthermore, rSmKI-1 significantly increased the production of interferon gamma, interleukin (IL)-10, and IL-6 in vaccinated mice, maintaining a Th1/Th2-type balanced protective response. CONCLUSIONS: rSmKI-1 generated partial protection against schistosomiasis mansoni in the murine model of infection and could be developed as part of a combination vaccine with other vaccine candidates to provide an even more solid level of protection.
Authors: Juan Hernández-Goenaga; Julio López-Abán; Anna V Protasio; Belén Vicente Santiago; Esther Del Olmo; Magnolia Vanegas; Pedro Fernández-Soto; Manuel Alfonso Patarroyo; Antonio Muro Journal: Front Immunol Date: 2019-11-01 Impact factor: 7.561
Authors: Fábio Mambelli; Bruno P O Santos; Suellen B Morais; Enrico G T Gimenez; Duana C Dos S Astoni; Amanda D Braga; Rafaela S Ferreira; Flávio A Amaral; Mariana T Q de Magalhães; Sergio C Oliveira Journal: PLoS Negl Trop Dis Date: 2021-01-19
Authors: Julio López-Abán; Belén Vicente; Elías Kabbas-Piñango; Juan Hernández-Goenaga; Javier Sánchez-Montejo; María Aguiriano; Esther Del Olmo; Magnolia Vanegas; Manuel Alfonso Patarroyo; Antonio Muro Journal: J Clin Med Date: 2021-01-24 Impact factor: 4.241
Authors: Suellen B Morais; Barbara C Figueiredo; Natan R G Assis; Jane Homan; Fábio S Mambelli; Rodrigo M Bicalho; Cláudia Souza; Vicente P Martins; Carina S Pinheiro; Sergio C Oliveira Journal: Front Immunol Date: 2018-07-30 Impact factor: 7.561